Jason Hsu, MD
Ophthalmology · Plymouth Meeting, PANPI 1548218787
Payments from drug & device makers
Across 95 payments — averaging $10,603 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$544K
- Jazz Pharmaceuticals Inc.$258K
- Boehringer Ingelheim$86K
- Astellas Pharma Global Development$81K
- Regeneron$13K
- Chugai Pharmaceutical Co., Ltd.$13K
- plus $11K from 5 others
Across 5 payments — averaging $862.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$4K
What the payments were for
- Consulting fees$8,56648%
- Travel & lodging$9,08150%
- Food & beverage$3352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 37 | $544,117 |
| Jazz Pharmaceuticals Inc. | 5 | $258,491 |
| Boehringer Ingelheim | 5 | $86,358 |
| Astellas Pharma Global Development | 4 | $81,127 |
| Regeneron | 4 | $13,379 |
| Chugai Pharmaceutical Co., Ltd. | 4 | $13,086 |
| Boehringer Ingelheim International GmbH | 29 | $5,818 |
| Astellas Pharma US Inc | 1 | $2,500 |
| Neurotech Pharmaceuticals, Inc. | 2 | $2,138 |
| Biosense Webster, Inc. | 1 | $133 |
| Genentech USA, Inc. | 3 | $96 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$2,500
- QDOT MICRO$133
How this compares
$1,007,244 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 168 | $7,959 |
| Ketorolac Tromethamine | 69 | $1,386 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 67 | $965 |
| Ofloxacin | 58 | $759 |
| Dorzolamide Hcl | 18 | $242 |
| Brimonidine Tartrate | 20 | $214 |
| ErythromycinErythromycin Base | 13 | $198 |
| Diclofenac Sodium | 13 | $134 |
| Timolol Maleate | 16 | $90 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Plymouth Meeting
- Carl RegilloPlymouth Meeting$3.2M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Mitchell FinemanPlymouth Meeting$1.3M
- Allen HoPlymouth Meeting$1.3M
- Yoshihiro YonekawaPlymouth Meeting$916K
- Michael KlufasPlymouth Meeting$528K
- Sonia MehtaPlymouth Meeting$442K
- Ajay KuriyanPlymouth Meeting$320K
- Mohammed KhanPlymouth Meeting$175K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.